HealthStudy: Some Weight-Loss Drugs Might Be Able To Lower the Risk of 42 Health ConditionsWhat's going on: A study published in Nature Medicine yesterday suggests that drugs like Ozempic and Wegovy might be able to do more than control diabetes and treat obesity. After analyzing data from nearly 2.5 million patients in the Department of Veterans Affairs’s (VA) system, researchers weren’t surprised to see that the GLP-1 drugs helped combat cardiovascular and kidney diseases. However, they weren’t expecting the drug to help lower the risk of substance abuse disorders, suicidal ideation, and dozens of diseases. Researchers also found GLP-1 drugs helped reduce the risk of dementia by 8% and Alzheimer’s by 12%. The lead researcher said no one designed GLP-1 drugs thinking they would be able to treat neurodegenerative diseases, but it’s more of a “side gig.” What it means: There have been plenty of smaller studies on what GLP-1 drugs can do, but none as large or comprehensive as this one. Still, researchers found GLP-1 use is linked to gastrointestinal issues, arthritis, heartburn, and even stomach paralysis in rare cases. The dataset also has some shortcomings since it pulled the data from the VA population, which tends to be older, less racially diverse, and more male than the rest of the US. GLP-1 drugs have exploded in popularity in recent years, with nearly 1 in 8 US adults reporting that they have used or are using the drug to help with weight loss, treat diabetes, or prevent heart attacks. While health experts say these drugs could lead to off-label uses, it’s unclear whether the Food and Drug Administration (FDA) would approve such uses anytime soon. Related: Where Does Health Secretary Nominee RFK Jr. Stand on GLP-1 Drugs? (ABC News) |